Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 71Active not recruiting 21Unknown 17Terminated 17Recruiting 17Withdrawn 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Glioma 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peritoneal Neoplasms 2Osteosarcoma 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Diffuse Intrinsic Pontine Glioma 2Warts 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

lenvatinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Thyroid Neoplasms × Clear all
NCT03139747 2021-10-15

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Thomas Jefferson University

Phase 2 Suspended
5 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡